Logo image of RCUS

ARCUS BIOSCIENCES INC (RCUS) Stock Fundamental Analysis

NYSE:RCUS - New York Stock Exchange, Inc. - US03969F1093 - Common Stock - Currency: USD

7.95  -0.55 (-6.47%)

After market: 8.34 +0.39 (+4.91%)

Fundamental Rating

2

Taking everything into account, RCUS scores 2 out of 10 in our fundamental rating. RCUS was compared to 558 industry peers in the Biotechnology industry. Both the profitability and financial health of RCUS have multiple concerns. While showing a medium growth rate, RCUS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RCUS had negative earnings in the past year.
RCUS had a negative operating cash flow in the past year.
In the past 5 years RCUS reported 4 times negative net income.
In multiple years RCUS reported negative operating cash flow during the last 5 years.
RCUS Yearly Net Income VS EBIT VS OCF VS FCFRCUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

RCUS's Return On Assets of -33.82% is fine compared to the rest of the industry. RCUS outperforms 63.08% of its industry peers.
With a Return On Equity value of -73.63%, RCUS perfoms like the industry average, outperforming 53.23% of the companies in the same industry.
Industry RankSector Rank
ROA -33.82%
ROE -73.63%
ROIC N/A
ROA(3y)-24.17%
ROA(5y)-17.02%
ROE(3y)-55.15%
ROE(5y)-36.73%
ROIC(3y)N/A
ROIC(5y)N/A
RCUS Yearly ROA, ROE, ROICRCUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

RCUS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RCUS Yearly Profit, Operating, Gross MarginsRCUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

RCUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RCUS has been increased compared to 1 year ago.
RCUS has more shares outstanding than it did 5 years ago.
RCUS has a worse debt/assets ratio than last year.
RCUS Yearly Shares OutstandingRCUS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
RCUS Yearly Total Debt VS Total AssetsRCUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of -0.95, we must say that RCUS is in the distress zone and has some risk of bankruptcy.
RCUS has a Altman-Z score (-0.95) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.09 indicates that RCUS is not too dependend on debt financing.
RCUS has a worse Debt to Equity ratio (0.09) than 64.70% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z -0.95
ROIC/WACCN/A
WACC8.77%
RCUS Yearly LT Debt VS Equity VS FCFRCUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 5.37 indicates that RCUS has no problem at all paying its short term obligations.
RCUS has a Current ratio of 5.37. This is comparable to the rest of the industry: RCUS outperforms 55.91% of its industry peers.
A Quick Ratio of 5.37 indicates that RCUS has no problem at all paying its short term obligations.
The Quick ratio of RCUS (5.37) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.37
Quick Ratio 5.37
RCUS Yearly Current Assets VS Current LiabilitesRCUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

RCUS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -34.73%.
RCUS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -40.51%.
The Revenue has been growing by 76.65% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-34.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2180%
Revenue 1Y (TTM)-40.51%
Revenue growth 3Y-12.33%
Revenue growth 5Y76.65%
Sales Q2Q%-80.69%

3.2 Future

RCUS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.53% yearly.
Based on estimates for the next years, RCUS will show a very strong growth in Revenue. The Revenue will grow by 25.84% on average per year.
EPS Next Y-49.84%
EPS Next 2Y-22.47%
EPS Next 3Y-13.19%
EPS Next 5Y10.53%
Revenue Next Year-55.16%
Revenue Next 2Y-24.03%
Revenue Next 3Y-4.63%
Revenue Next 5Y25.84%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RCUS Yearly Revenue VS EstimatesRCUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B
RCUS Yearly EPS VS EstimatesRCUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RCUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RCUS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCUS Price Earnings VS Forward Price EarningsRCUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCUS Per share dataRCUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

A cheap valuation may be justified as RCUS's earnings are expected to decrease with -13.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.47%
EPS Next 3Y-13.19%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RCUS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARCUS BIOSCIENCES INC

NYSE:RCUS (6/27/2025, 8:04:00 PM)

After market: 8.34 +0.39 (+4.91%)

7.95

-0.55 (-6.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners93.01%
Inst Owner Change15.22%
Ins Owners5.27%
Ins Owner Change5.16%
Market Cap841.83M
Analysts82.11
Price Target28.75 (261.64%)
Short Float %11.45%
Short Ratio9.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.36%
Min EPS beat(2)-8.41%
Max EPS beat(2)19.13%
EPS beat(4)3
Avg EPS beat(4)6.85%
Min EPS beat(4)-8.41%
Max EPS beat(4)19.13%
EPS beat(8)6
Avg EPS beat(8)18.05%
EPS beat(12)10
Avg EPS beat(12)15.44%
EPS beat(16)11
Avg EPS beat(16)46.35%
Revenue beat(2)0
Avg Revenue beat(2)-18.34%
Min Revenue beat(2)-24.87%
Max Revenue beat(2)-11.8%
Revenue beat(4)2
Avg Revenue beat(4)9.48%
Min Revenue beat(4)-24.87%
Max Revenue beat(4)49.28%
Revenue beat(8)5
Avg Revenue beat(8)46.71%
Revenue beat(12)8
Avg Revenue beat(12)40.71%
Revenue beat(16)9
Avg Revenue beat(16)75.47%
PT rev (1m)-7.19%
PT rev (3m)-13.41%
EPS NQ rev (1m)-2.74%
EPS NQ rev (3m)-9.6%
EPS NY rev (1m)-7.24%
EPS NY rev (3m)-10.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.96%
Revenue NY rev (1m)-2.71%
Revenue NY rev (3m)-27.1%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.97
P/FCF N/A
P/OCF N/A
P/B 1.59
P/tB 1.59
EV/EBITDA N/A
EPS(TTM)-4.19
EYN/A
EPS(NY)-4.65
Fwd EYN/A
FCF(TTM)-2.86
FCFYN/A
OCF(TTM)-2.83
OCFYN/A
SpS1.33
BVpS5.01
TBVpS5.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.82%
ROE -73.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.17%
ROA(5y)-17.02%
ROE(3y)-55.15%
ROE(5y)-36.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30%
Cap/Sales 2.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.37
Quick Ratio 5.37
Altman-Z -0.95
F-Score2
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)153.33%
Cap/Depr(5y)249.37%
Cap/Sales(3y)9.4%
Cap/Sales(5y)7.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-34.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2180%
EPS Next Y-49.84%
EPS Next 2Y-22.47%
EPS Next 3Y-13.19%
EPS Next 5Y10.53%
Revenue 1Y (TTM)-40.51%
Revenue growth 3Y-12.33%
Revenue growth 5Y76.65%
Sales Q2Q%-80.69%
Revenue Next Year-55.16%
Revenue Next 2Y-24.03%
Revenue Next 3Y-4.63%
Revenue Next 5Y25.84%
EBIT growth 1Y-74.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-39.02%
EBIT Next 3Y-9.26%
EBIT Next 5YN/A
FCF growth 1Y5.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.46%
OCF growth 3YN/A
OCF growth 5YN/A